Recently, it has been reported that immune checkpoint inhibitors, such as programmed cell death-1 (PD-1) and programmed death-ligand 1 (PD-L1) activate T cells and can induce autoimmune-disease-like symptoms [106–108]. This evidence concerns the gene PDCD1 and autoimmune disease.